Hepatitis C Weekend Update; Clinical trials

[Guest guest]

Hepatitis C Weekend Update; Clinical trials

Are you interested in learning about or participating in a hepatitis C virus (HCV) clinical research study? If so, choosing to participate in a clinical trial is an important personal decision. To learn what a clinical trial is, the pros and cons of participating, who is eligible to participate, and many more commonly asked questions CLICK HERE This will provide you with detailed information about clinical trials. In addition, it is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials. To find a clinical trial in your area CLICK HERESourceLearning About Clinical TrialsSummary of investigational Hepatitis C drugs presented at the 2011 EASL ConferenceHepatitis C New Drug Pipeline; New drugs in development for the treatment of hepatitis Chttp://www.hcvdrugs.com/Quick Reference guide to better understand the various “Phases†of clinical trials:PHASE I TRIALS: Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of

effectiveness; may include healthy participants and/or patients.PHASE II TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling.http://www.clinicaltrials.gov/1RecruitingStudy of BMS-650032 With Peginterferon Alfa-2a Plus RibavirinCondition:Hepatitis C VirusInterventions:Drug: BMS-650032; Drug: Placebo; Drug: Peginterferon Alfa-2a; Drug: Ribavirin2RecruitingGS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusCondition:Hepatitis C, ChronicInterventions:Drug: GS-5885; Drug: GS-9451; Biological: peginterferon alfa-2a; Drug:

ribavirin tablet3RecruitingOral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCondition:Hepatitis C, ChronicInterventions:Drug: GS-5885 placebo; Drug: GS-5885 tablet; Drug: GS-9451 placebo; Drug: GS-9451 tablet; Drug: Tegobuvir placebo; Drug: Tegobuvir; Biological: peginterferon alfa-2a; Drug: ribavirin tablet4RecruitingA Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCondition:Hepatitis C, ChronicInterventions:Drug: Tegobuvir (GS-9190); Drug: GS-9451; Biological: Pegasys®; Drug: Copegus®; Drug: Tegobuvir placebo; Drug: GS-9451 placebo5Not yet recruitingGS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeCondition:Chronic Hepatitis CInterventions:Drug: GS-5885, GS-9451, PEG , RBV; Drug: PEG, RBV6RecruitingGS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCondition:Hepatitis C, ChronicInterventions:Drug:

GS-5885; Drug: Tegobuvir; Drug: GS-9451; Drug: ribavirin tablet7RecruitingRomiplostim in Treating Hepatitis C-Infected Patients With ThrombocytopeniaConditions:Hepatitis C Infection; ThrombocytopeniaInterventions:Biological: romiplostim; Drug: ribavirin; Other: placebo; Biological: PEG-interferon alfa-2a; Other: laboratory biomarker analysis8RecruitingA Randomized, Active-Control Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 InfectionCondition:Hepatitis CInterventions:Drug: Bavituximab; Drug: Pegylated interferon (PEG-IFN)9RecruitingCHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) SubjectsCondition:Chronic Hepatitis CInterventions:Drug: ChronVac-C + SOC; Drug: SOC10RecruitingEfficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus InfectionCondition:Hepatitis C, ChronicInterventions:Drug: PEG-rIL-29; Drug: Peginterferon alfa-2a; Drug: Ribavirin11RecruitingStudy of SCY-635, Pegasys and Copegus in Hepatitis CCondition:Hepatitis C InfectionInterventions:Drug: Placebo; Drug: SCY-635; Drug: peginterferon alfa 2a; Drug: Ribavirin12RecruitingSafety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCondition:Hepatitis CInterventions:Biological: Pegylated Interferon Lambda (pegIFNλ); Drug: BMS-790052 (NS5A Inhibitor); Drug: Ribavirin (RBV); Drug: BMS-650032 (NS3 Protease Inhibitor); Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a); Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor); Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor); Drug: Placebo for Ribavirin (RBV)13RecruitingFilibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 SubjectsConditions:Hepatitis; Hepatitis CInterventions:Drug: Filibuvir; Drug: Placebo14RecruitingPh IIA Study (SOC +/- NS5B)Condition:Hepatitis C VirusInterventions:Drug: BMS-791325; Drug: Placebo; Drug: Peg-interferon alfa-2a; Drug: Ribavirin15RecruitingSafety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C InfectionCondition:Genotype 1 Chronic Hepatitis CInterventions:Drug: GI-5005; Drug: Pegylated Interferon and Ribavirin16RecruitingS-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate in Preventing Liver Cancer in Patients With Chronic

Hepatitis C InfectionConditions:Infection; Liver CancerInterventions:Drug: S-adenosyl-L-methionine disulfate p-toluene-sulfonate; Other: placebo17RecruitingSafety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype-1 Patients With Chronic HCV InfectionCondition:Hepatitis CInterventions:Drug: Placebo; Drug: ANA598; Drug: Ribavirin; Drug: Pegylated Interferon18RecruitingEfficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-respondersCondition:Hepatitis C ChronicInterventions:Drug: DEB025 600 mg QD + SOC; Drug: DEB025 800 mg QD; Drug: placebo + SOC; Drug: DEB025 400 mg BID + SOC19RecruitingSafety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver EnzymesCondition:Hepatitis C, ChronicInterventions:Drug: Placebo;

Drug: PF-0413630920RecruitingMultiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C SubjectsCondition:Hepatitis CInterventions:Drug: miravirsen; Drug: saline21RecruitingEfficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced FibrosisCondition:Chronic Hepatitis

CInterventions:Drug: Ribavirin; Drug: Colchicine22RecruitingA Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM4)Condition:Hepatitis C, ChronicInterventions:Drug: Vaniprevir (600 mg b.i.d.); Drug: Vaniprevir (300 mg b.i.d.); Drug: Pegylated interferon (Peg-IFN); Drug: Ribavirin (RBV)23RecruitingAssess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic FibrosisCondition:Chronic Hepatitis CInterventions:Drug: Fuzheng Huayu; Drug: Placebo24RecruitingThalidomide Plus Peginterferon and Ribavirin in Patients With Interferon ResistanceCondition:Hepatitis CIntervention:Drug: thalidomide25Not yet recruitingChronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501Condition:ThrombocytopeniaIntervention:Drug: E5501 (previously known as AKR-501 monomaleate)26RecruitingStudy in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis CConditions:HCV Infection; Liver TransplantationInterventions:Biological: MBL-HCV1; Other:

0.9% Sodium chloride Placebo27RecruitingGradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver TransplantConditions:Hepatitis C; Hepatitis C, ChronicInterventions:Procedure: Continuous maintenance immunosuppressive therapy; Procedure: Immunosuppression withdrawal; Procedure: Liver transplant28RecruitingRibavirin Pre-treatment Followed

by Combined Standard Therapy in Hepatitis C Virus (HCV) RecipientsCondition:Hepatitis CIntervention:Drug: ribavirin pre-treatment29RecruitingRetreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4Conditions:Liver Cirrhosis; Hepatitis C Virus; HIV InfectionIntervention:Drug: Pegylated interferon alfa-2a and Ribavirin30RecruitingTelaprevir In HIV-HCV Coinfected Patients Who Had Previously Failed A Peginterferon-Ribavirin RegimenConditions:Hepatitis C, Chronic; HIV InfectionInterventions:Drug: Telaprevir; Biological: peginterferon alfa-2a; Drug: Ribavirin31RecruitingExtension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCVCondition:Chronic Hepatitis CIntervention:Drug: SCV-0732Not yet recruitingTMC435-TiDP16-C213 - Phase III, Open-Label Roll-Over Trial of TMC435 + Peginterferon Alfa-2A and Ribavirin for Patients Who Participated in Control Group of a TMC435 StudyCondition:Hepatitis CIntervention:Drug: TMC43533RecruitingA Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CConditions:Chronic Hepatitis C Infection; Genotype 1Interventions:Drug: recombinant variant of interferon-alpha 2b; Drug: Peginterferon alfa-2a34RecruitingA Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic

Hepatitis CConditions:Chronic Hepatitis C Virus Infection; Genotype 1; Treatment-Experienced Patients; RelapsesInterventions:Drug: Interferon α-5; Drug: Interferon-α5 plus Interferon-α 2b; Drug: Interferon α-2b (INTRON® A)35RecruitingA Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1Condition:Chronic Hepatitis CInterventions:Drug: CF 102; Drug: Placebo36Not yet recruitingClinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.Condition:Chronic Hepatitis CIntervention:Biological: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin37RecruitingRandomized Placebo-controlled Trial Evaluating the Safety and

Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis Conditions:Acute Hepatitis A; Acute Hepatitis B; Acute Hepatitis C; Acute Hepatitis E; Acute EBV Hepatitis; Acute CMV HepatitisInterventions:Dietary Supplement: Silymarin; Other: Lactose monohydrate38RecruitingEfficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN α2a in Chronic Hepatitis C Genotype 2 and 3 naïve PatientsConditions:Hepatitis C; Chronic PainInterventions:Drug: DEB025 1000 mg QD; Drug: DEB025 600 mg QD + RBV 400 mg BID; Drug: DEB025 800 mg QD + RBV 400 mg BID;

Drug: DEB025 600 mg QD + peg-IFNα2a once weekly; Drug: SOC (peg-IFNα2a once weekly + RBV 400 mg BID)39RecruitingStudy of the Impact of Nitazoxanide on Chronic Hepatitis PatientsCondition:Hepatitis CInterventions:Drug: Placebo; Drug: Nitazoxanide40RecruitingA Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in

Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionCondition:Chronic Hepatitis C Virus InfectionInterventions:Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a41RecruitingDose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy AloneCondition:Hepatitis CIntervention:Drug: Interleukin-742RecruitingSafety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive SubjectsCondition:Hepatitis CInterventions:Drug: ACH-0141625; Drug: Placebo; Drug: Pegylated Interferon alpha-2a; Drug: ribavirin43RecruitingY- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis CConditions:Self Efficacy; Hepatitis CIntervention:Drug:

pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg44RecruitingStudy of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected SubjectsConditions:Hepatitis C Virus (HCV); Chronic Hepatitis CInterventions:Drug: ABT-267; Drug: Peginterferon alpha-2a (pegIFN); Drug: Ribavirin (RBV); Drug: Placebo45RecruitingRibavirin Dose Optimization for the Treatment of Hepatitis

CCondition:Chronic Hepatitis CIntervention:Drug: Peg-interféron alpha-2a (Pegasys) and Ribavirin (RBV)46RecruitingStudy to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of CareCondition:Chronic Hepatitis CInterventions:Drug: BMS-790052; Drug: BMS-650032; Drug: Pegylated-interferon alfa-2a; Drug: Ribavirin47RecruitingIntravenous Silibinin in Combination With Peg-interferon and Ribavirin in NonrespondersCondition:Hepatitis CIntervention:Drug: Silibinin48RecruitingMK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003)Condition:Hepatitis C, ChronicInterventions:Drug: MK-5172; Drug: Boceprevir; Drug: Placebo for MK-5172; Drug: Placebo for Boceprevir; Drug: Peg-interferon alfa-2b; Drug:

Ribavirin49RecruitingA Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis CCondition:Hepatitis C, ChronicInterventions:Drug: danoprevir; Drug: ritonavir; Drug: RO5024048; Drug: Copegus; Drug: Pegasys50RecruitingStudy Comparing Reduction

and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1Condition:Chronic Hepatitis CInterventions:Drug: IFN alfa-2b XL 27 MUI + Ribavirin; Drug: IFN alfa-2b XL 36 MUI + Ribavirin; Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin51RecruitingStudy to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Not Been Treated With Standard of CareCondition:Chronic Hepatitis

CInterventions:Drug: PSI-7977; Drug: BMS-790052; Drug: Ribavirin52RecruitingIntrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)Condition:Hepatitis CIntervention:Drug: Telaprevir53RecruitingA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in

Treatment-Naive Patients With Chronic Hepatitis C Virus InfectionCondition:Hepatitis C, ChronicInterventions:Drug: danoprevir; Drug: ritonavir; Drug: peginterferon alfa-2a [Pegasys]; Drug: Copegus; Drug: daneprovir54RecruitingOpen-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3Condition:Chronic Hepatitis C InfectionIntervention:Drug: PSI-7977 with and without ribavirin (RBV) and/or Pegylated Interferon (PEG-IFN)55RecruitingHigh-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1Condition:Chronic Hepatitis CInterventions:Drug: Peginterferon; Drug: Ribavirin56RecruitingPSI-7977 With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6Condition:Hepatitis C, ChronicIntervention:Drug: PSI-7977 with PEG/RBV57RecruitingSafety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis CConditions:Chronic Hepatitis C; Oxidative StressInterventions:Dietary Supplement: silymarin; Dietary Supplement: green tea extract (EGCG)58RecruitingEfficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral InfectionCondition:Recurrent Hepatitis

CInterventions:Drug: Everolimus; Drug: standard treatment59RecruitingStandard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-RespondersCondition:Hepatitis C Virus (HCV) InfectionInterventions:Drug: CTS-1027; Drug: pegylated interferon; Drug: Ribavirin; Drug: Placebo60RecruitingA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCondition:Chronic Hepatitis C, Hepatitis C, Hepatitis C Virus (HCV)Interventions:Drug: ABT-450/r; Drug: ABT-333; Drug: ribavirin61RecruitingStudy the Relationship Between Obesity and Hepatitis C ReplicationCondition:Hepatitis CIntervention:Drug: Pioglitazone,

Prednisone62RecruitingA Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment FailuresConditions:HIV; HCV; HCV Genotype 1Intervention:Drug: Nitazoxanide63RecruitingA Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C PatientsCondition:Hepatitis CInterventions:Drug: LCQ908; Drug:

Placebo64RecruitingSafety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I InfectionCondition:Chronic Hepatitis CIntervention:Drug: CT-01165RecruitingEfficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With

Chronic Viral Hepatitis C Nonresponders to Antiviral TherapyCondition:Chronic Hepatitis CIntervention:Drug: vitamin D66RecruitingSafety and Efficacy Study in Hepatitis C Patients With PHN121Condition:Hepatitis C Virus InfectionIntervention:Drug: PHN12167Not yet recruitingSafety and Antiviral Activity of IDX184 in Combination

With Pegylated Interferon and Ribavirin for 12 WeeksCondition:Hepatitis C, ChronicIntervention:Drug: IDX18468RecruitingThe Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic EncephalopathyConditions:Hepatic Encephalopathy; Hepatitis C; Liver CirrhosisIntervention:Drug: Rifaximin (drug)69RecruitingA Study on The Combination of RO5024048 And Ritonavir-Boosted Danoprevir With And Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)Condition:Hepatitis C, ChronicInterventions:Drug: RO5024048; Drug: danoprevir; Drug: ritonavir; Drug: ribavirin [Copegus]; Drug: Copegus placebo70RecruitingDose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)Condition:Hepatitis

CIntervention:Drug: Interleukin-771RecruitingBoceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/RibavirinConditions:HCV Coinfection; HIV-1 InfectionIntervention:Drug: Boceprevir, Peg-interferon alfa 2b and Ribavirin72RecruitingBrief Intervention for Drug Misuse in the Emergency DepartmentConditions:Substance

Abuse Detection; Acquired Immunodeficiency Syndrome; Hepatitis B; Hepatitis C; Brief Intervention; HIV InfectionsIntervention:Behavioral: Brief motivational intervention73Not yet recruitingTMC435HPC3002 - 3-Year Follow up of Patients After Administration of TMC435 for the Treatment of Chronic Hepatitis C.Condition:Hepatitis CIntervention:Other: Blood samples74RecruitingPegintron to Treat Plexiform Neurofibromas in Children and Young AdultsConditions:Neurofibromatosis Type 1; Plexiform NeurofibromaIntervention:Drug: PEG-interferon alfa-2b75RecruitingStudy of PEG-Intron for Plexiform NeurofibromasCondition:Plexiform NeurofibromaIntervention:Drug: PEG-Intron76RecruitingInterferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral TherapyCondition:HIV InfectionIntervention:Drug: Interferon Alpha 2b77RecruitingA Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory ThrombocytopeniaConditions:Anemia, Aplastic; Anemia, Hypoplastic; ThrombocytopeniaInterventions:Drug:

Eltrombopag (Promacta); Drug: Eltrombopag78RecruitingANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIVCondition:HepatitisIntervention:Drug: Peg-interféron alpha 2a + ribavirine79RecruitingTMC435-TiDP16-C216 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected PatientsCondition:Hepatitis CInterventions:Drug: Placebo; Drug: TMC43580RecruitingA Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected PatientsCondition:Hepatitis C, ChronicInterventions:Drug: TMC435; Drug: Placebo81RecruitingA Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Failed to Respond to Previous IFN-based TherapyCondition:Hepatitis C, ChronicIntervention:Drug: TMC43582RecruitingTMC435HPC3007 - Phase III Trial of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous TherapyCondition:Hepatitis CInterventions:Drug: TMC435; Drug: Placebo83RecruitingTMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected PatientsCondition:Hepatitis CInterventions:Drug: TMC435; Drug: Placebo84RecruitingRaltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsConditions:HIV Infection; Liver Failure; Liver TransplantationIntervention:Drug: Raltegravir

potassium85RecruitingPegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)Condition:Chronic Hepatitis CIntervention:Drug: Peginterferon alfa-2a and Ribavirin86Not yet recruitingVaniprevir

Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)Condition:Hepatitis C, ChronicInterventions:Drug: vaniprevir; Drug: Placebo to vaniprevir; Biological: peg-IFN alfa-2b; Drug: ribavirin87RecruitingStudy of a Novel Therapeutic Vaccine for Hepatitis C VirusCondition:Hepatitis CInterventions:Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut ; Ad6NSmut88RecruitingA Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based TherapyCondition:Hepatitis C, ChronicIntervention:Drug: TMC43589RecruitingA Study of TMC435 in Genotype 1, Hepatitis C-Iinfected Patients (Treatment-Naive or Interferon-Based Treatment Experienced)Condition:Hepatitis C, ChronicIntervention:Drug: TMC43590Not yet recruitingA Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3Condition:Hepatitis C, ChronicInterventions:Drug: Pegylated interferon alfa 2b; Drug: Ribavirin91RecruitingDouble Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral LoadCondition:Hepatitis CInterventions:Drug: DFPP + Peg-IFN + RBV; Drug: Peg-IFN +

RBV92RecruitingInterferon and Ribavirin Treatment in Patients With HemoglobinopathiesCondition:HemoglobinopathiesIntervention:Drug: PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin93RecruitingPegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Dialysis Patients With Chronic Hepatitis CCondition:Chronic Hepatitis

CInterventions:Drug: Pegylated interferon alfa-2a plus low dose ribavirin; Drug: Pegylated interferon alfa94RecruitingA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.Condition:Hepatitis C, ChronicIntervention:Drug: peginterferon alfa-2a [Pegasys]95RecruitingStudy of a New MVA Vaccine for Hepatitis C

VirusCondition:Hepatitis CInterventions:Biological: MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut; Biological: AdCh3NSmut ; MVA-NSmut96RecruitingSafety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCondition:Hepatitis C, ChronicInterventions:Drug: BI 207127; Drug: BI 201335; Drug: RBV97RecruitingTMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.Conditions:Hepatitis C; HIVInterventions:Drug: ETR/telaprevir; Drug: TMC278/telaprevir; Drug: telaprevir/ETR; Drug: telaprevir/TMC27898RecruitingEfficacy and Safety Study of DEB025/Alisporivir Combined to Standard Therapy (Peg-IFN and Ribavirin) in Chronic Hepatitis C Genotype 1 naïve PatientsCondition:Hepatitis C,

ChronicInterventions:Drug: Standard of Care (SOC: Peg-IFN once weekly + Ribavirin BID) + DEB025; Drug: SOC + DEB025 400 mg; Drug: SOC + DEB025; Drug: Placebo + SOC for 48 weeks99RecruitingEfficacy and Safety of BI201335 in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Genotype 1 Hepatitis C Infected Patients (Double Blind, Randomized, Placebo Controlled, Phase III)Condition:Hepatitis CInterventions:Drug: BI201335; Drug: PegIFN/RBV100RecruitingPeginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVRCondition:Chronic Hepatitis CIntervention:Drug: Pegylated interferon alfa-2a + ribavirin101RecruitingHerpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis CConditions:Hepatitis C Virus Infection; Infection; Herpesvirus 2, HumanIntervention:Drug:

Valacyclovir102RecruitingA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.Condition:Hepatitis C, ChronicInterventions:Drug: peginterferon alfa-2a [Pegasys]; Drug: Copegus103Not yet recruitingA Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)Condition:Hepatitis C, ChronicInterventions:Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]104Not yet recruitingA Study of

the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination TherapyCondition:Hepatitis C, ChronicInterventions:Drug: peginterferon alfa 2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]105RecruitingOpen Label Study to Evaluate the Safety, Efficacy, Viral Kinetics, Genetic, Epigenetic, and Proteomic Expression of Weekly Peginterferon Alpha 2a

and Ribavirin Therapy for Chronic Hepatitis C in Latino Subjects With and Without HIV Co-infectionConditions:Hepatitis C; HIVIntervention:Drug: Pegylated interferon with ribavirin106Not yet recruitingA Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow ResponseCondition:Hepatitis C, ChronicInterventions:Drug: peginterferon alfa-2a [Pegasys]; Drug: COPEGUS107Recruiting100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)Conditions:Sustained Virologic Response; IL28B PolymorphismInterventions:Drug: peginterferon alfa 2a (pegasys); Drug: peginterferon alfa-2a (pegasys)108RecruitingA Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1Condition:Hepatitis C,

ChronicInterventions:Drug: danoprevir; Drug: ritonavir; Drug: placebo; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin109Not yet recruitingBMS-790052 Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis CCondition:Hepatitis CInterventions:Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Peg-Interferon Alfa-2a; Drug: Ribavirin110RecruitingA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.Condition:Hepatitis C, ChronicInterventions:Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]111RecruitingA Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in

Patients With Chronic Hepatitis CCondition:Hepatitis C, ChronicInterventions:Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin112RecruitingStudy to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 PatientsCondition:Hepatitis C, ChronicInterventions:Drug: pegylated interferon alpha-2b; Drug: Ribavirin; Drug: pegylated Interferon alpha-2b113RecruitingHepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral TherapyCondition:Hepatitis CIntervention:Drug: Pegylated interferon-alfa-2b and ribavirin114RecruitingEXtended Therapy in Hepatitis C Genotype 3 Infected PatientsCondition:Chronic Hepatitis CIntervention:Drug: Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)115RecruitingThe Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus RibavirinCondition:Chronic Hepatitis CInterventions:Drug: Pioglitazone; Drug: Acarbose; Drug: Metformin116RecruitingPeginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular CarcinomaConditions:Chronic Hepatitis C; NeoplasmsIntervention:Drug: Peginterferon alfa-2a

plus ribavirin117RecruitingHigh-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4Condition:Chronic Hepatitis C Genotype One or FourIntervention:Drug: ribavirin118Not yet recruitingTreatment of Recently Acquired Hepatitis C Virus InfectionCondition:Acute Hepatitis CInterventions:Drug: Peginterferon alfa-2a; Drug:

Ribavirin119RecruitingLow-Dose Peg-Interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCCCondition:Hepatitis C, ChronicIntervention:Drug: interferon-alfa-2b and ribavirin120Not yet recruitingA

Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis CCondition:Healthy Volunteer, Hepatitis CInterventions:Drug: RO5428029; Drug: placebo121RecruitingAn Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)Condition:Hepatitis CIntervention:122RecruitingRibavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1Condition:Hepatitis CInterventions:Drug: Ribavirin "loading" dose given; Drug: "Priming" dose of ribavirin given; Drug: Group C ("Standard-of-Care")123RecruitingTMC647055HPC1001 - First-in-human Trial to Examine Safety,

Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected PatientsCondition:Hepatitis CInterventions:Drug: Placebo; Drug: TMC647055; Drug: TMC435124RecruitingFollow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath TestCondition:Chronic Hepatitis BIntervention:Device: 13C Methacetin Breath Test (BreathID)125RecruitingPioglitazone Versus Placebo in Association With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Patients With Insulin ResistanceConditions:Chronic Hepatitis C; Insulin ResistanceInterventions:Drug: Pioglitazone; Drug: Placebo126RecruitingA Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6

PatientsCondition:Chronic Hepatitis CInterventions:Drug: Peginterferon alfa2a; Drug: Ribavirin127RecruitingQuality of Life in Chronic Hepatitis C (Study P05278)Conditions:Hepatitis C, Chronic; Genotype 1; HCV-1Interventions:Biological: Peginterferon alfa-2b; Drug: Ribavirin128RecruitingInjecting Drug Use Community Intervention TrialConditions:HIV; Hepatitis C; Syphilis; HSV-2; HIV

InfectionsIntervention:Behavioral: Intervention129RecruitingA Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus InfectionCondition:Hepatitis C, ChronicIntervention:Drug: GS-6620130RecruitingQuantification of Liver Iron Overload and Steatosis Using Magnetic Resonance ImagingConditions:Iron Overload; Metabolic Syndrome X; Hepatitis B; Hepatitis C; Alcohol AbuseIntervention:Device: Magnetic resonance imaging multiecho gradient-echo sequence131Not yet recruitingFluvastatin, Simvastatin to Improve Interferon SensitivityCondition:Chronic Hepatitis CIntervention:Drug: statin132RecruitingA Open-label Study to Evaluate the Relative Bioavailability of IDX184 and Food Effect in Healthy Male SubjectsCondition:Hepatitis CIntervention:Drug: IDX184133Not yet recruitingSafety of Raltegravir When Given as Part of HIV Therapy in HIV/HCV Coinfected IndividualsCondition:HIV/ Hepatitis C Co-InfectionInterventions:Drug: Raltegravir (Isentress); Drug: Efavirenz (Sustiva)134RecruitingPrevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis CCondition:Hepatitis CIntervention:135RecruitingThe Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic

SteatohepatitisCondition:HepatitisInterventions:Drug: Pioglitazone; Drug: placebo136RecruitingIncreasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C PatientsConditions:Obesity; Insulin Resistance; Metabolic Syndrome; Hepatitis CInterventions:Drug: Orlistat; Behavioral: Dietary and Lifestyle modification educational sessions137RecruitingPegasys

Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis BCondition:Chronic Hepatitis BInterventions:Drug: Pegasys plus Entecavir; Drug: Entecavir138RecruitingPilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant RecipientsConditions:Hepatitis C; Evidence of Liver TransplantationIntervention:Drug: ITX 5061139RecruitingInterferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV MedsConditions:HIV Infection; Hepatitis C Virus InfectionInterventions:Drug: Anti-HIV Agents; Drug: raltegravir; Drug: Emtricitabine and tenofovir disoproxil fumarate140RecruitingBaclofen to Reduce Alcohol Use in Veterans With HCVConditions:Hepatitis C; Alcohol Use DisordersInterventions:Drug: baclofen; Drug: placebo141RecruitingSafety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)Condition:Hepatitis CInterventions:Drug: MK-6325; Drug: Placebo to MK-6325142RecruitingImproving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had ChemotherapyConditions:Breast Cancer; Colon Cancer; Bladder CancerInterventions:Drug: Glycosylated Recombinant Human Interleukin-7; Biological: Diphtheria-Tetanus Vaccine; Biological: Polio Vaccine;

Biological: Pneumaococcal Vaccine; Biological: Hepatitis A Vaccine; Biological: Hepatitis B Vaccine; Biological: Influenza Vaccine; Biological: PhiX 174143RecruitingA Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis BConditions:HIV Coinfection; Hepatitis C; Hepatitis B; HepatotoxicityInterventions:Drug: Maraviroc; Drug: Placebo144RecruitingClinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral TherapyCondition:Hepatitis CInterventions:Drug: Silymarin; Drug: Placebo145Not yet recruitingVarious Insulin Regimens for Diabetic Inpatients With Cirrhosis TrialConditions:Type 2 Diabetes; Liver CirrhosisInterventions:Drug: Glargine & Glulisine; Drug: Regular insulin; Drug: NPH & regular insulin146RecruitingRibavirin, Its Dosing RegimeCondition:Hepatitis CIntervention:Drug: Ribavirin147Not yet recruitingImproved Prevention of Perinatal Hepatitis B TransmissionCondition:Liver FibrosisIntervention:Biological: Sci B vac148Not yet recruitingGenetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin LymphomaConditions:Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Mantle Cell Lymphoma RecurrentInterventions:Procedure: peripheral blood stem cell transplantation (PBSCT); Biological: filgrastim; Genetic: polymerase chain reaction; Biological: rituximab; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Drug: plerixafor; Procedure: autologous hematopoietic stem cell transplantation149Not yet recruitingSulfation of Bile Acids as a Biomarker for Hepatobiliary DiseasesCondition:Hepatobiliary DiseasesIntervention:150Not yet recruitingJapanese Bridging Study Conducted in the United StatesCondition:Hepatitis C VirusInterventions:Drug: BMS-791325; Drug: Placebo151RecruitingStudy of Bavituximab and Sorafenib In Patients With Advanced Liver CancerConditions:Hepatocellular Carcinoma; Liver CancerIntervention:Drug: bavituximab and sorafenib152RecruitingA Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCCCondition:Advanced Hepatocellular Carcinoma (HCC)Interventions:Drug: OSI-906; Other: Placebo153RecruitingDose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e AntigenCondition:Hepatitis B VirusInterventions:Drug: pegIFN; Drug: pegIFNα-2a154RecruitingHCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With FosamprenavirConditions:Chronic HIV Infection; HCV CoinfectionIntervention:Drug:

Fosamprenavir155RecruitingSorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver CancerCondition:Liver CancerInterventions:Drug: everolimus; Drug: sorafenib tosylate; Other: questionnaire administration; Procedure: computed tomography; Procedure: magnetic resonance imaging; Procedure: quality-of-life assessment156RecruitingSafety and Immunogenicity of New Formulations of GlaxoKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)Conditions:Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; TetanusInterventions:Biological: GSK217744; Biological: Infanrix hexa™; Biological: Prevenar 13®157Not yet recruitingHyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not

Responding to Standard TherapyCondition:Asymptomatic Chronic HCV rsIntervention:Drug: Bovine Colostrum Powder158Not yet recruitingStudy to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy SubjectsCondition:Hepatitis CInterventions:Drug: Midazolam; Drug: BMS-791325159RecruitingEffects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)Conditions:HIV; Hepatitis CInterventions:Behavioral: Motivational interviewing; Behavioral: Educational intervention160RecruitingProspective Trial of Vaccine Responses in Childhood Cancer SurvivorsConditions:Pediatric Cancers; Multiple DiseasesInterventions:Biological: Immunization Schedule patients <7 years.; Biological: Immunization Schedule patients > or = to 7 years and <11 years of age; Biological: Immunization Schedule patients > or = to 11 years of age161Not yet

recruitingSafety and Immunogenicity of a Killed Oral Cholera Vaccine in InfantsConditions:Cholera; Diarrhea; Vibrio InfectionsInterventions:Biological: Bivalent killed oral cholera vaccine; Biological: Killed Escherichia coli K12 placebo162RecruitingA Study of V419 Given Concomitantly With Prevnar 13â„¢ and RotaTeqâ„¢ (V419-006 AM1)Conditions:Bacterial Infections; Virus

DiseasesInterventions:Biological: V419; Biological: PENTACELâ„¢; Biological: Prevnar 13â„¢; Biological: RotaTeqâ„¢; Biological: Modified process hepatitis B vaccine163Not yet recruitingFibrinogen as an Alternative to FFP in Aortic Surgery.Condition:Coagulopathy in Patients Having Thoraco-Abdominal Aneurysm RepairInterventions:Biological: Fibrinogen concentrate; Biological: Fresh Frozen Plasma164RecruitingTrial Comparing Different Ribavirin Dosages and Different Duration of Treatment in Combination With Pegylated Interferon in Patients With Genotype 2 and 3Condition:Chronic HepatitisIntervention:Drug: Peginterferon alpha-2a + Ribavirin165RecruitingStudy to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With

Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B(CHB).Condition:Chronic Hepatitis BInterventions:Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a166RecruitingAugmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis BCondition:Chronic Hepatitis BInterventions:Drug: pegylated interferon a-2a; Drug: Entecavir167Not yet recruitingPEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B PatientsCondition:Chronic Hepatitis BInterventions:Drug: Peginterferon alfa-2a; Drug: Nucleos(t)ide analogue168Not yet recruitingEfficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver

FailureCondition:Acute on Chronic Hepatic FailureInterventions:Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO); Drug: Placebo169RecruitingModified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult SubjectsCondition:HIV InfectionIntervention:Biological: Hepavax-Gene170RecruitingEvaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)Conditions:Acquired Immunodeficiency Syndrome; HIV InfectionsInterventions:Drug: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line); Drug: abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line); Drug: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)171RecruitingImmunogenicity and Safety of GSK Biologicals' Infanrix Hexa in

Infants.Conditions:Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis Vaccines; TetanusIntervention:Biological: Infanrixâ„¢ hexa172RecruitingMethadone Maintenance & HIV Risk in UkraineCondition:Opioid DependenceIntervention:Drug: Methadone173RecruitingInfluence of Antiviral Treatment to

the Long-Term Prognosis of Patients With Chronic HBV InfectionCondition:Hepatitis B, ChronicInterventions:Drug: lamivudine; Drug: Telbivudine; Drug: Enticavir; Drug: Adefovir Dipivoxil Tablets174RecruitingA Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With TerlipressinCondition:Hepatorenal Syndrome Type 1Interventions:Drug: Terlipressin; Drug: Placebo175RecruitingSafety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the USConditions:Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.; Papillomavirus VaccinesIntervention:Biological: GSK580299, GSK Biological's HPV vaccine176RecruitingCohort of Young Adults Infected With HIV Since Birth or During ChildhoodConditions:HIV Infection; Young AdultIntervention:Biological: blood sampling, specific biological exams and biobank and self administered

questionnaires177RecruitingProbiotics for Portal HypertensionConditions:Cirrhosis; Varices, EsophagealIntervention:Drug: Propranolol, Norfloxacin, VSL#3

http://Hepatitis Cnewdrugs.blogspot.com/2011/07/hepatitis-c-weekend-update-clinical.html